What’s Next for Sangamo Therapeutics, Inc. (SGMO) After Today’s Huge Increase?

December 7, 2017 - By Migdalia James

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.79, from 0.8 in 2017Q1. It increased, as 13 investors sold Sangamo Therapeutics, Inc. shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported.
Oppenheimer Asset Inc, a New York-based fund reported 7,746 shares. 7,836 were accumulated by Bnp Paribas Arbitrage Sa. Balyasny Asset Limited Liability Com has invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Group Inc One Trading L P reported 235,958 shares. Barclays Public Ltd Llc reported 34,008 shares. Gp invested in 44,268 shares or 0% of the stock. Northern Tru has 947,832 shares for 0% of their portfolio. Gilder Gagnon Howe & Ltd Limited Liability Company accumulated 0.01% or 58,378 shares. Aperio Group Inc Ltd Liability Co owns 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 12,291 shares. Geode Cap Limited Liability Corp has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 727,615 shares. Frontier Capital Management Commerce Ltd reported 0.03% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Employees Retirement Association Of Colorado invested in 0% or 25,992 shares. Opaleye accumulated 580,000 shares. Hanson Mcclain holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 1,000 shares. Moreover, Goldman Sachs has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 100,176 shares.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 5.20% or $0.85 during the last trading session, reaching $17.2. About 1.37 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since December 7, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.
The move comes after 8 months positive chart setup for the $1.45B company. It was reported on Dec, 7 by Barchart.com. We have $18.06 PT which if reached, will make NASDAQ:SGMO worth $72.70M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.23 earnings per share, down 64.29 % or $0.09 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 53.33 % negative EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Sangamo Biosciences had 21 analyst reports since August 8, 2015 according to SRatingsIntel. The company was maintained on Saturday, August 8 by JP Morgan. The firm has “Hold” rating given on Thursday, August 10 by Piper Jaffray. Jefferies maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, September 2 with “Buy” rating. The rating was reinitiated by Jefferies with “Buy” on Thursday, June 22. The firm earned “Buy” rating on Friday, October 13 by Jefferies. As per Monday, August 14, the company rating was maintained by Wedbush. As per Friday, September 4, the company rating was maintained by Cowen & Co. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Outperform”. Jefferies maintained the shares of SGMO in report on Tuesday, September 12 with “Buy” rating. Wedbush downgraded the shares of SGMO in report on Tuesday, November 1 to “Neutral” rating.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Prnewswire.com which released: “Sangamo Announces Strategic Investment In Manufacturing And Appointment Of …” on November 09, 2017, also Nasdaq.com with their article: “Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher” published on November 16, 2017, Seekingalpha.com published: “Sangamo’s Powerful Pipeline Drives Significant Upside” on November 17, 2017. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Fool.com and their article: “Here’s Why Sangamo Therapeutics Rose as Much as 14.9% Thursday” published on November 30, 2017 as well as Seekingalpha.com‘s news article titled: “Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases” with publication date: December 07, 2017.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.45 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.